This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's Stop Trading: GW Pharmaceuticals Is for Real

NEW YORK (TheStreet) -- "I think this is becoming a non-speculative stock," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said of GW Pharmaceuticals (GWPH) on CNBC's "Cramer's Stop Trading" segment. 

The company has released its preliminary data for Epidiolex, its cannabinoid treatment aimed at treatment-resistant epilepsy in children. 

Cramer argued that the U.S. doesn't seem to understand the importance of medical marijuana, as it would be illegal for companies to create the non-laced marijuana treatment that GW Pharmaceuticals, a British-based company, has. 

After 12 weeks, the drug showed at least a 50% reduction in seizures for 48% of the patients, with 15% of patients reportedly being seizure-free. 

Cramer said he believes the Food and Drug Administration will approve this treatment, as it is proving helpful to these children. 

He concluded that GW Pharmaceuticals is a "real company, doing real things."

-- Written by Bret Kenwell in Petoskey, Mich.

5 Reasons So Many Seniors Fall Victim to I.D. Theft

Pro Golfers Like Mickelson Hit Hole in One on Investing Tips

It's Time for Your Midyear Financial Checkup

Why Would Anyone Want to Buy Yelp?

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GWPH $43.62 0.00%
AAPL $94.27 0.00%
FB $101.00 0.00%
GOOG $684.12 0.00%
TSLA $143.67 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs